Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model

Abstract The aim of this study is to investigate the effects of bevacizumab in a rat model of ovarian hyperstimulation syndrome (OHSS) and compare with cabergoline. The study was performed with 24 rats in four main groups (one non-stimulated control and three OHSS treatment groups; bevacizumab, cabergoline and placebo). The rats were randomly assigned to four experimental groups (six rats per group). Efficacy of treatment was assessed on 29th day by measuring weight gain, number of eggs, presence of ascites and ovarian weight. Peritoneal fluid levels of vascular endothelial growth factor (VEGF) were measured using an enzyme-linked immunosorbent assay. Ovarian weights were significantly higher in the OHSS groups than the control group. Ovarian weights in OHSS placebo group were found to be higher than those in OHSS-treatment groups (p = 0.002). VEGF levels were found increased in the OHSS-placebo group compared with the control group (p < 0.05). This increase was not seen in the OHSS groups treated with either bevacizumab or cabergoline. We demonstrate in this study that bevacizumab can lower VEGF production and ovarian weight in rats treated with gonadotropins.

[1]  Agustin A. Garcia,et al.  Bevacizumab and ovarian cancer , 2013, Therapeutic advances in medical oncology.

[2]  D. Ezcurra,et al.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment , 2012, Reproductive Biology and Endocrinology.

[3]  A. Hellström,et al.  On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review , 2011, Acta paediatrica.

[4]  M. Çaydere,et al.  Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. , 2011, Fertility and sterility.

[5]  M. Bilotas,et al.  Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis , 2011, Reproductive Sciences.

[6]  C. Simón,et al.  Physiology and pathology of ovarian hyperstimulation syndrome. , 2010, Seminars in reproductive medicine.

[7]  M. Spasojevic,et al.  Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. , 2010, American journal of surgery.

[8]  M. Yılmazer,et al.  Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam , 2010, Acta obstetricia et gynecologica Scandinavica.

[9]  R. Ferriani,et al.  Ovarian hyperstimulation syndrome: pathophysiology and prevention , 2010, Journal of Assisted Reproduction and Genetics.

[10]  A. Nugent,et al.  Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. , 2009, Investigative ophthalmology & visual science.

[11]  L. Nardo,et al.  Symposium--Update on prediction and management of OHSS: introduction to guest symposium. , 2009, Reproductive biomedicine online.

[12]  C. Simón,et al.  Prevention of OHSS – dopamine agonists , 2009 .

[13]  J. Shu,et al.  Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. , 2008, Chinese Medical Journal.

[14]  C. Racowsky,et al.  Coasting vs. cryopreservation of all embryos for prevention of ovarian hyperstimulation syndrome in in vitro fertilization. , 2008, Fertility and sterility.

[15]  C. Simón,et al.  Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. , 2006, Endocrinology.

[16]  M. Iqbal,et al.  Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. , 2003, Endocrine journal.

[17]  H. Okamura,et al.  Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. , 1998, Human reproduction.

[18]  H. Okamura,et al.  Role of progesterone in capillary permeability in hyperstimulated rats. , 1997, Human reproduction.

[19]  D. Connolly,et al.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.

[20]  E. Lindenbaum,et al.  Ovarian hyperstimulation in rats. , 1980, European Journal of Obstetrics, Gynecology, and Reproductive Biology.

[21]  L. Szabo,et al.  Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. , 2012, Human reproduction.

[22]  C. Simón,et al.  Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists. , 2009, Reproductive biomedicine online.

[23]  C. Carizza,et al.  Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. , 2008, Reproductive biomedicine online.